Controlled clinical trials and postmarketing experience

被引:0
|
作者
Linden, M
机构
来源
PSYCHOPHARMAKOTHERAPIE | 1997年 / 4卷 / 02期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The evaluation of any therapy, i.e. pharmacotherapy or a psychotherapy follows a stepwise process. Marketing authorization will be granted by the authorities after successful completion of a series of controlled trials. But it is generally accepted that results of controlled clinical trials cannot be generalized automatically to routine treatment. Thus, a separate evaluation of therapy under conditions of routine treatment has to be carried out, i.e. postmarketing surveillance or evaluation of therapy in so-called phase IV. There is a variety of methods and designs in phase IV research, for example, recording spontaneous observations regarding adverse events, epidemiologic surveys, stimulated spontaneous observations, case control studies and cohort studies, database analyses, interviews or experimental studies on special questions. Drug utilization observation studies are of particular importance since they are a very frequent study type. There are drug-epidemiologic studies with non-reactive assessment methods collecting and interrelating information on patient, illness, prescription, course and outcome. A protocol describing purpose of study and methodologic procedure is scientifically indispensable. Results of a drug utilization observation study on venlafaxine show to what extent hospitalized patients differ from those in ambulatory treatment. This is true for example for history of treatment or severity of illness. It can, therefore, be inferred that results from one treatment setting or from a particular group of physicians cannot automatically be generalized to another.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 50 条
  • [1] Tolerability of sumatriptan: clinical trials and postmarketing experience
    Welch, KMA
    Feniuk, W
    Mansbach, H
    Scott, A
    CEPHALALGIA, 2001, 21 (08) : 855 - 856
  • [2] Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience
    Gracon, SI
    Knapp, MJ
    Berghoff, WG
    Pierce, M
    DeJong, R
    Lobbestael, SJ
    Symons, J
    Dombey, SL
    Luscombe, FA
    Kraemer, D
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (02): : 93 - 101
  • [3] Electronic Data-Capturing Technology for Clinical Trials Experience with a Global Postmarketing Study
    Lu, Zhengwu
    IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE, 2010, 29 (02): : 95 - 102
  • [4] Differences between clinical trials and postmarketing use
    Martin, K
    Bégaud, B
    Latry, P
    Miremont-Salamé, G
    Fourrier, A
    Moore, N
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (01) : 86 - 92
  • [5] FAMOTIDINE - POSTMARKETING CLINICAL-EXPERIENCE
    SAIGENJI, K
    FUKUTOMI, H
    NAKAZAWA, S
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1987, 22 : 34 - 40
  • [6] Safety of Gadobutrol, a New Generation of Contrast Agents Experience From Clinical Trials and Postmarketing Surveillance
    Voth, Matthias
    Rosenberg, Martin
    Breuer, Josy
    INVESTIGATIVE RADIOLOGY, 2011, 46 (11) : 663 - 671
  • [7] A descriptive analysis of postmarketing requirement studies and clinical trials
    Choi, Lauren
    Etchey, Beverly
    Billings, Monisha
    Lee, Cathryn
    Weil, Kathleen M.
    Boxwell, Debra
    Edelberg, Helen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [8] A postmarketing clinical experience study of Metadate® CD
    Dirksen, SJH
    D'Imperio, JM
    Birdsall, D
    Hatch, SJ
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (07) : 371 - 380
  • [9] The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs
    Vray, M
    Hamelin, B
    Jaillon, P
    THERAPIE, 2005, 60 (04): : 345 - 349
  • [10] Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience
    Hacke, W
    Brott, T
    Caplan, L
    Meier, D
    Fieschi, C
    von Kummer, R
    Donnan, G
    Heiss, WD
    Wahlgren, NG
    Spranger, M
    Boysen, G
    Marler, JR
    NEUROLOGY, 1999, 53 (07) : S3 - S14